The limited response rate of cancer patients treated with dendritic cell (DC)-based vaccines indicates that vast improvements remain necessary. In many murine tumour models it has been demonstrated that the use of innate triggers (e.g. TLR triggers) in the maturation of DC results in higher efficacy. However, as few of these innate triggers are generated clinical grade, there remains a great necessity to fill the gap between fundamental mouse studies and a clinical trial in humans. In the present study we used a TLR2/4-agonist (FMKp which is available clinical grade) in combination with IFN-γ (FI-cocktail) in the maturation of elutriated monocyte-derived DC and compared it with the most used DC in current clinical trials (TNF-α/PGE-2, i.e. TP-cocktail). In addition to the assessment of CD4+ T cell polarizing capacity, we compared the quantity and intrinsic quality of induced CD8+ T cells of 2 different DC maturation protocols with all cells from the same donor. Besides differences in the cytokine profile, which could be coupled to increased Th1 and Th17 polarization, we demonstrate in this study that FMKp/IFN-γ matured DC are twice as effective in inducing cytotoxic T cells against known tumor antigens. Both DCs induced phenotypically equivalent effector memory CD8+ T cells that did not show a significant difference in their intrinsic capacity to kill tumor cells. These findings point to the therapeutic applicability of FI-DC as superior inducers of functional antigen-specific T cells. Their increased chemokine secretion is suggestive of a mechanism by which these DC may compensate for the limited migration observed for all ex vivo cultured DC when applied in patients.
BanchereauJPaluckaAK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol2005; 5: 296–306.
2.
JeffordMMaraskovskyECebonJDavisID. The use of dendritic cells in cancer therapy. Lancet Oncol2001; 2:343–53.
3.
SteinmanRMDhodapkarM. Active immunization against cancer with dendritic cells: the near future. Int J Cancer2001; 94:459–73.
4.
JonuleitHKühnUMüllerGSteinbrinkKParagnikLSchmittEKnopJEnkAH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol1997; 27:3135–42.
5.
SallustoFLanzavecchiaA. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med1994; 179:1109–18.
DavisIDJeffordMParentePCebonJ. Rational approaches to human cancer immunotherapy. J Leukoc Biol2003; 73:3–29.
8.
GilboaENairSKLyerlyHK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother1998; 46:82–7.
9.
RosenbergSAYangJCRestifoNP. Cancer immunotherapy: moving beyond current vaccines. Nat Med2004; 10:909–15.
10.
PaluckaKUenoHFayJBanchereauJ. Harnessing dendritic cells to generate cancer vaccines. Ann NY Acad Sci2009; 1174:88–98.
11.
RidgwayD. The first 1000 dendritic cell vaccinees. Cancer Invest2003; 21:873–86.
12.
KalinskiPHilkensCMSnijdersASnijdewintFGKapsenbergML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol1997; 159:28–35.
13.
BanerjeeDKDhodapkarMVMatayevaESteinmanRMDhodapkarKM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood2006; 108:2655–61.
14.
LeglerDFKrausePScandellaESingerEGroettrupM. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol2006; 176:966–73.
15.
LuftTJeffordMLuetjensP. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood2002; 100:1362–72.
16.
ScandellaEMenYLeglerDFGillessenSPriklerLLudewigBGroettrupM. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood2004; 103:1595–601.
17.
BoccaccioCJacodSKaiserABoyerAAbastadoJPNardinA. Identification of a clinical-grade maturation factor for dendritic cells. J Immunother2002; 25:88–96.
18.
FrascaLNassoMSpensieriFFedeleGPalazzoRMalavasiFAusielloCM. IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol2008; 180:1471–81.
19.
JongmansWTiemessenDMvan VlodropIJMuldersPFOosterwijkE. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother2005; 28:480–7.
20.
ZhuQEgelstonCVivekanandhanAUematsuSAkiraSKlinmanDMBelyakovIMBerzofskyJA. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci USA2008; 105:16260–5.
21.
TrumpfhellerCCaskeyMNchindaGLonghiMPMizeninaOHuangYSchlesingerSJColonnaMSteinmanRM. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA2008; 105:2574–9.
22.
RamakrishnaVVasilakosJPTarioJDJrBergerMAWallacePKKelerT. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med2007; 5:5.
23.
PrinsRMCraftNBruhnKWKhan-FarooqiHKoyaRCStripeckeRMillerJFLiauLM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol2006; 176:157–64.
MaggiEGiudiziMGBiagiottiR. Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med1994; 180:489–95.
26.
SalgamePAbramsJSClaybergerCGoldsteinHConvitJModlinRLBloomBR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science1991; 254:279–82.
27.
HolmesBJMacAryPANobleAKemenyDM. Antigen-specific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells. Eur J Immunol1997; 27:2657–65.
28.
NobleAZhaoZSCantorH. Suppression of immune responses by CD8 cells. II. Qa-1 on activated B cells stimulates CD8 cell suppression of T helper 2 responses. J Immunol1998; 160:566–71.
29.
Vukmanovic-StejicMVyasBGorak-StolinskaPNobleAKemenyDM. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood2000; 95:231–40.
30.
CroftMCarterLSwainSLDuttonRW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med1994; 180:1715–28.
31.
GettAVSallustoFLanzavecchiaAGeginatJ. T cell fitness determined by signal strength. Nat Immunol2003; 4:355–60.
32.
GoxeBLatourNChokriMAbastadoJPSalcedoM. Simplified method to generate large quantities of dendritic cells suitable for clinical applications. Immunol Invest2000; 29:319–36.
33.
BohnenkampHRNollT. Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application. Cytotechnology2003; 42:121–31.
34.
JeanninPRennoTGoetschL. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol2000; 1:502–9.
35.
SallustoFMackayCRLanzavecchiaA. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol2000; 18:593–620.
36.
FontenotJDGavinMARudenskyAY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol2003; 4:330–6.
37.
Chavez-GalanLArenas-Del AngelMCZentenoEChavezRLascurainR. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol2009; 6:15–25.
38.
GillmoreRXueSAHollerA. Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res2006; 12:34–42.
39.
MiconnetICosteIBeermannFHaeuwJFCerottiniJCBonnefoyJYRomeroPRennoT. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J Immunol2001; 166:4612–9.
40.
KaiserABercoviciNAbastadoJPNardinA. Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur J Immunol2003; 33:162–71.
41.
SchlunsKSLefrancoisL. Cytokine control of memory T-cell development and survival. Nat Rev Immunol2003; 3:269–79.
42.
KimDMonieATsaiYCHeLWangMCHungCFWuTC. Enhancement of CD4(+) T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Ther2008; 15:1176–83.
43.
KimCHRottLKunkelEJGenoveseMCAndrewDPWuLButcherEC. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest2001; 108:1331–9.
44.
SallustoFLanzavecchiaAMackayCR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today1998; 19:568–74.
MuranskiPBoniAAntonyPA. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood2008; 112:362–73.
49.
WangJIoan-FacsinayAvan der VoortEIHuizingaTWToesRE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol2007; 37:129–38.
50.
de VriesIJLesterhuisWJBarentszJO. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol2005; 23:1407–13.
51.
PrinceHMWallDMRitchieD. In vivo tracking of dendritic cells in patients with multiple myeloma. J Immunother2008; 31:166–79.
52.
LesimpleTNeidhardEMVignardV. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res2006; 12:7380–8.
